OCCIDENT

Pléiade Venture est une Société de Capital Risque Française. Elle investit sur le long terme, sans horizon de sortie prédéterminé. Elle soutient les entreprises innovantes de tous secteurs, hors biotech. Elle dispose de plus de 100 M€ d'actifs et investit de 0,5 à 3 M€ par opération. Elle est financée par des entrepreneurs qui forts de leur expérience désirent contribuer activement à de nouveaux succès. Elle est animée par une équipe en liaison étroite avec une vingtaine d’entrepreneurs contributifs. Nos différencesEvergreen: Pléiade Venture, à la différence des fonds, investit ses fonds propres et réinvestit ses plus-values, sans horizon de sortie prédéterminé. Actionnaire stable et pérenne, Pléiade Venture s’adapte au projet long terme de l’entrepreneur. Contributif: Notre capital est constitué d'entrepreneurs issus de secteurs variés. Ils réinvestissent une partie de leur patrimoine et partagent leur expérience avec les dirigeants de nos participations. Un quart de nos actionnaires sont d’ailleurs les fondateurs d'entreprises que nous avons financées. Galaxie: Pléiade Venture s’inscrit dans un ensemble de structures indépendantes : Pléiade Investissement (Capital Développement, LBO et retournement) Pléiade AM (Fonds d'actions cotées) autour d’une idée commune : « Faire ensemble, et faire autrement, ce que nous ne ferions pas seuls ! ». Nos CritèresStade: Seed, Series A Secteurs: Tous sauf : Biotechnologies, Entertainment, Immobilier Montant: 0,5 M€ à 3 M€, Seul ou en coinvestissement

Lingotto’s Innovation Fund is a new $600mm+ AUM crossover (public & private) fund focused on making concentrated and long-term investments in companies operating at the cutting edge of technological and business-model innovation. Core to our investment thesis is the fact that market returns are dominated by extreme structural winners – we seek to identify decades-long secular trends and the management teams best positioned to capitalize on them in the early years. The senior team has a notable history of private investments including: OpenAI, SpaceX, Alibaba, Coupang, Stripe, Databricks, Spotify, Airbnb, Tempus, Recursion, Ginkgo Bioworks, Palantir, Epic Games, Joby Aviation, Indigo, Aira, Humane, H2 Green Steel. The Innovation Fund is co-managed by James Anderson (CIO & Managing Partner) and Morgan Samet (Co-Head & Managing Partner). James has over 40 years of investment experience – most recently as a Partner at Baillie Gifford, where he managed over £100bn in AUM throughout his tenure. As head of the firm’s flagship fund, the Scottish Mortgage Investment Trust, he delivered a +1,555% return vs. +354% for the FTSE all-world benchmark (between April 2000 and March 2022). He was instrumental in the firm’s move into private investing starting with Alibaba in 2012. Morgan has over 19 years of experience in private and public market investing. She has previously worked at Belfer Management, Pzena Investment Management, Thomas H. Lee Partners, and Goldman Sachs. She received her MBA from Harvard Business School. The Innovation Fund is a part of Lingotto, a $4.5bn+ investment management company supported with permanent capital from Exor and additional external LPs. Exor is one of Europe’s largest publicly traded holding companies. Its assets include companies like Stellantis (Fiat, Chrysler, Citroen), Ferrari, Philips, Juventus Football Club, the Economist and Christian Louboutin. Exor’s CEO is John Elkann (Chairman of Ferrari); its Chairman is Nitin Nohria (Executive Chairman of Thrive Capital and former Dean of Harvard Business School). Lingotto’s Chairman is George Osborne, former UK chancellor.

LiquidMetal Ventures is a newly established venture capital fund based in Boston, aiming at investing in early-stage (Seed, Angel, and pre-A round) in a minority group, particularly deep-tech startups. LiquidMetal Ventures is based on deep-tech start-up communities and has a unique advantage in reaching out to ‘off-the-market’ early-stage deals and cooperating with peer VC funds tightly to reduce the risk, overall a high return could be expected. LiquidMetal Ventures focuses on biotech and healthcare, carbon neutrality, AI and data, infrastructure, and consumer tech. There is a huge tide of startups among Boston entrepreneurs in the US on the way. We would like to be the first to check VC with the founders. Investment FocusBioTech Medical Device Sustainability AI & Data Science Advanced Energy Technology Robotics & Advanced Manufacturing

Our business is to turn scientists into entrepreneurs who can save lives and save the planet (we call this “human and planetary health”). Personal, 1 on 1, with IndieBio’s Team We are not an assembly line. You are not a widget. Every startup is unique and needs devoted attention. Most startup programs have a meeting with you once a week. We talk to you almost every day. We sit with you, desk to desk, as we work. These rapid touchpoints speed up your iteration cycles and are critical to your evolution into a successful startup. You get direct access to the team that helped build so many iconic companies over the years. Most accelerators are designed to spot the one company in 10 that might be big one day. At IndieBio, every startup matters. You are our first priority. Your success is our only business model. We only invest in companies that come through our accelerator. Our Alumni are Our Greatest Asset All new startups get the benefit of a trusted community with 199 alumni who are happy to share their wisdom. Going through IndieBio is an incredible bonding experience. We teach a philosophy and mindset that is uniquely ours. You’ll become emotionally and intellectually attached to your fellow batch mates. You’ll remember them the rest of your life. This deep connection informs the next years to come. IndieBio is our startups’ birthplace. Everyone visits home. Every generation of startups gets the benefit of alumni help, and then they repay the favor to the new batch. First, we can start funding you and working with you earlier, long before you’re ready to be in the intensive program. We’ve done this up to 9 months in advance. So even if you haven’t graduated yet, or haven’t yet gone full-time on the startup, we recommend you still apply. We Believe in Diversity 44% female. First, second, and third time founders. 36 nationalities. Post-docs and corporates. Ages 21 to 75. Diversity is a core thesis for IndieBio. We find talent that many others overlook. Some of the greatest companies of tomorrow are hiding in plain sight, today, right now. It’s just that nobody listens long and hard enough to recognize the brilliance and the potential. If other investors have told you that you’re “too early,” well, that’s our sweet spot. We’ve funded paper plans, where no science has been done yet–and created hugely successful companies that way. Perhaps the greatest endorsement is how many alumni have returned to IndieBio to create their second company. Choose SOSV as your Partner IndieBio’s parent is SOSV, which has $1 billion in assets under management, and is consistently a Top Quartile VC. SOSV runs programs around the world in robotics, biotech, mobile ecommerce, fintech, automated manufacturing, food, and cryptocurrencies. The firm was founded by Sean O’Sullivan, who had also been an entrepreneur and a humanitarian. In 2020, during the heat of the pandemic – when others were retreating – we were the most active investor in the US. We are now the 4th most active early stage investor in India. Our climate tech portfolio alone is worth over $6 billion. Partners for the Long-term The journey begins with $525,000 and our intense program. But we continue to invest meaningfully in every round. 80% of our capital is deployed post-accelerator. We recommend choosing your investors wisely. We offer the biggest checks in the accelerator industry, but that’s just the beginning. SOSV, our venture fund, is spread around the globe and manages $1.4 billion (as of September 16, 2022). We target a long-term ownership of around 10%, and we continue to invest at Seed through Series C. We are a long-term partner, not just a first-check accelerator. At IndieBio, we are in touch with thousands of investors, and we have co-invested with well over 400 firms. The SOSV network is even greater.

Unreasonable inventors are combining cutting edge scientific discoveries with the world's biggest challenges to build the next generation of global companies. These are the companies we create and invest in at Main Sequence. We have over $500m under management from lean-in LPs who help our portfolio to prosper. We are investing in the difficult to build companies others struggle to support. Our co-founder is Australia's $1.3b annual budget science agency - CSIRO We invest from seed to Series B, starting our journey as early as possible, driving advantage into our portfolio. Our Advantage Deep tech inventors need more. We have custom built Main Sequence to be ready to help you solve some of the world's greatest challenges with science. We are hands-on and have built a services offering to support founders alongside our capital. Our story Main Sequence was created by CSIRO to address the ‘valley of death’ between research and commercialisation. It solves the world’s greatest challenges by turning our scientific breakthroughs into the next century’s giants. Main Sequence’s origins within CSIRO reflect its commitment to amplifying connections between industry, research and infrastructure to accelerate deep technology development, and reinvesting economic returns from commercialisation back into science. CSIRO Innovation Funds 1 and 2 managed by Main Sequence, have invested in 39 companies since establishment in 2017. These companies have created over 1,200 jobs by working with partners in industry, CSIRO, and 22 Australian universities. The $240 million first CSIRO Innovation Fund , built on a cornerstone investment by government and CSIRO has completed its portfolio and invested in 27 companies since establishment in 2017. The second $300 million CSIRO Innovation Fund commenced investing mid-2021 and had already invested in 12 companies by the end of 2021. Following the Government’s announcement on 1 February 2022 of a reform agenda to accelerate commercialisation of research and collaboration with industry, including $150m support for CSIRO investment in future CSIRO Innovation Funds, Main Sequence welcomes the opportunity to continue to work closely with universities to commercialise Australian research and build Australian companies addressing global challenges. Each of our portfolio companies has some advantage delivered by either one of Australia's 43 universities or an industrial research organisation such as CSIRO. In some cases this exists before we invest, in others we facilitate it as part of the companies pathway to scale and impact.

We invest in opportunities backed by deep science. Xora is an early-stage investment platform of Temasek. We typically invest as a lead or co-lead investor in the Seed and Series A rounds, and later rounds (via our parent company). While we are not limited by geography, we prioritize opportunities that possess a strong linkage with the Singapore science & technology ecosystem. Leveraging the Temasek global network of investors and operating companies, we are active partners to ambitious founders building the next generation of impactful, world-changing companies. Our Team Our team possesses strong technical domain expertise in both physical and life sciences, and the intersection thereof, and are steeped in the nuances of early-stage deep science investing and venture building. We are global citizens with business experience in major markets. Our principles guide our engagement process and our investment decisions.We start with the people on the journey and a shared vision of the future. ​ We look for dogged persistence, unbounded creativity, acute self-awareness, a sense of urgency, and a passion for impact. We embrace both the technical and people complexity of science-based opportunities. ​ We welcome early and frequent contact and appreciate the opportunity to inform an emerging narrative. ​ We prefer brainstorming to pitches, and relationships to transactions. ​ We commit more than capital; we pledge our mindshare and our network.